{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:53:53Z","timestamp":1793336033214,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jtha.2023.03.016","type":"journal-article","created":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T15:04:36Z","timestamp":1679756676000},"page":"1737-1740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets"],"prefix":"10.1016","volume":"21","author":[{"given":"Jecko","family":"Thachil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Sholzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.03.016_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2141.1958.tb03830.x","article-title":"Haemophilia and related conditions: a survey of 187 cases","volume":"4","author":"Biggs","year":"1958","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.03.016_bib2","first-page":"246","article-title":"Deuterohemophilia: plasma thromboplastin factor B deficiency: plasma thromboplastin component (PTC) deficiency, Christmas disease","volume":"9","author":"Aggeler","year":"1954","journal-title":"hemophilia B. Blood"},{"key":"10.1016\/j.jtha.2023.03.016_bib3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.V35.3.409.409","article-title":"Obituary: Paul M Aggeler MD","volume":"35","author":"Wallerstein","year":"1970","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.016_bib4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.016_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2141.1969.tb01355.x","article-title":"Two types of haemophilia (A+ and A\u2212): a study of 48 cases","volume":"17","author":"Denson","year":"1969","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.03.016_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jcp.21.2.160","article-title":"An investigation of three patients with Christmas disease due to an abnormal type of factor IX","volume":"21","author":"Denson","year":"1968","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jtha.2023.03.016_bib7","first-page":"230","article-title":"An immunological investigation of hemophilia B with a tentative classification of the disease into five variants","volume":"32","author":"Girolami","year":"1977","journal-title":"Vox Sang"},{"key":"10.1016\/j.jtha.2023.03.016_bib8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0049-3848(75)90031-6","article-title":"Electroimmunoassay of factor IX in hemophilia B","volume":"7","author":"Orstavik","year":"1975","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.03.016_bib9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"Den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.jtha.2023.03.016_bib10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0033-1354426","article-title":"Defining severity of hemophilia: more than factor levels","volume":"39","author":"Pavlova","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2023.03.016_bib11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2141.1996.d01-1792.x","article-title":"Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII methods","volume":"94","author":"Rudzki","year":"1996","journal-title":"Br J Haemotol"},{"key":"10.1016\/j.jtha.2023.03.016_bib12","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1055\/s-0033-1356573","article-title":"Problems and solutions in laboratory testing for hemophilia","volume":"39","author":"Favaloro","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2023.03.016_bib13","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/jth.14242","article-title":"Nano-evidence for joint microbleeds in hemophilia patients","volume":"16","author":"Puetz","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.016_bib14","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1111\/hae.12995","article-title":"Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product","volume":"22","author":"Chowdary","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.016_bib15","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/hae.12987","article-title":"Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies","volume":"22","author":"Wyrwich","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.016_bib16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/hae.14300","article-title":"The function of extravascular coagulation factor IX in haemostasis","volume":"27","author":"Mann","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.016_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/MBC.0000000000000969","article-title":"Evaluating the potential benefits of the extravascular pool of factor IX","volume":"32","author":"Lillicrap","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2023.03.016_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","article-title":"New therapies using nonfactor products for patients with hemophilia and inhibitors","volume":"133","author":"Nogami","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.016_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/hae.13976","article-title":"Laboratory issues in gene therapy and emicizumab","volume":"27","author":"Bowyer","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.016_bib20","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1111\/hae.12759","article-title":"Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials","volume":"21","author":"Oladapo","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.016_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/hae.14525","article-title":"Quality of life in a large multinational haemophilia B cohort (The B-natural study) \u2013 unmet needs remain","volume":"28","author":"Berntorp","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.03.016_bib22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/jth.15570","article-title":"Invisible bleeds: lived experiences and barriers to care for men with hemophilia","volume":"20","author":"Arya","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.016_bib23","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni MV, Windyga J, Llin\u00e1s A, Goddard NJ, Mohan R, Poonnoose PM, Feldman BM, Lewis SZ, van den Berg HM, Pierce GF; WFH Guidelines for the Management of Hemophilia panelists and co-authors.WFH Guidelines for the management of hemophilia, 3rd ed. Haemophilia. 2020;26:1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046","DOI":"10.1111\/hae.14046"},{"key":"10.1016\/j.jtha.2023.03.016_bib24","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/jth.15397","article-title":"A\u00a0new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH","volume":"19","author":"van Galen","year":"2021","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623002477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623002477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:37:54Z","timestamp":1761536274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623002477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1538783623002477"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.03.016","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}